← Back to Analyst Consensus 
CMPX Buy
Compass Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 21
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 11, 2026 (16 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 23, 2026 | Craig-Hallum | maintain | Buy → Buy | — | 54% |
| Sep 23, 2026 | Citizens | maintain | Market Outperform → Market Outperform | — | 47% |
| Sep 23, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Sep 23, 2026 | Wedbush | downgrade | Outperform → Neutral | — | 58% |
| Sep 23, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Aug 7, 2026 | Piper Sandler | maintain | Overweight → Overweight | — | 54% |
| Apr 28, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Apr 28, 2026 | Citizens | reiterate | Market Outperform → Market Outperform | — | 47% |
| Apr 27, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Apr 27, 2026 | D. Boral Capital | maintain | Buy → Buy | — | 34% |
| Mar 24, 2026 | Guggenheim | reiterate | Buy → Buy | — | 52% |
| Jan 6, 2026 | D. Boral Capital | maintain | Buy → Buy | $30 | 34% |
| Jan 5, 2026 | William Blair | initiate | — → Outperform | $0 | 48% |
| Dec 3, 2025 | Cantor Fitzgerald | initiate | — → Overweight | $0 | 50% |
| Dec 3, 2025 | Citizens | initiate | — → Market Outperform | $10 | 47% |
| Dec 3, 2025 | Canaccord Genuity | initiate | — → Buy | $10 | 48% |
| Nov 5, 2025 | D. Boral Capital | maintain | Buy → Buy | $30 | 34% |
| Oct 6, 2025 | LifeSci Capital | initiate | — → Outperform | $10 | 57% |
| Aug 12, 2025 | D. Boral Capital | maintain | Buy → Buy | $32 | 34% |
| Aug 12, 2025 | Guggenheim | maintain | Buy → Buy | $12 | 52% |
| May 9, 2025 | Guggenheim | maintain | Buy → Buy | $10 | 52% |
| Apr 28, 2025 | D. Boral Capital | maintain | Buy → Buy | $32 | 34% |
| Apr 22, 2025 | Guggenheim | reiterate | Buy → Buy | $0 | 52% |
| Apr 21, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $24 | 44% |
| Apr 21, 2025 | D. Boral Capital | maintain | Buy → Buy | $32 | 34% |
| Apr 4, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $24 | 44% |
| Apr 2, 2025 | Guggenheim | reiterate | Buy → Buy | $12 | 52% |
| Apr 2, 2025 | Leerink Partners | upgrade | Market Perform → Outperform | $6 | 51% |
| Apr 1, 2025 | D. Boral Capital | maintain | Buy → Buy | $32 | 34% |
| Feb 27, 2025 | D. Boral Capital | maintain | Buy → Buy | $32 | 34% |
| Feb 25, 2025 | D. Boral Capital | maintain | Buy → Buy | $32 | 34% |
| Feb 24, 2025 | Guggenheim | initiate | — → Buy | $12 | 52% |
| Feb 19, 2025 | Piper Sandler | initiate | — → Overweight | $12 | 54% |
| Feb 10, 2025 | Jefferies | maintain | Buy → Buy | $8 | 52% |
| Jan 10, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| Jan 8, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $10 | 44% |
| Jan 8, 2025 | D. Boral Capital | maintain | Buy → Buy | $32 | 34% |
| Dec 23, 2024 | D. Boral Capital | initiate | — → Buy | $32 | 34% |
| Nov 15, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| Nov 12, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| Nov 11, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| Sep 16, 2024 | Ladenburg Thalmann | upgrade | Neutral → Buy | $5 | 45% |
| Aug 12, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| Aug 7, 2024 | Wedbush | reiterate | Outperform → Outperform | $8 | 58% |
| Aug 6, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| Jun 3, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| May 16, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| May 14, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| Apr 16, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $10 | 44% |
| Mar 22, 2024 | Wedbush | reiterate | Outperform → Outperform | $8 | 58% |
Price Target Trend
May 21, 2026 Latest: $5.45 Oct 25, 2026
EPS Estimates
0y $-0.48
Lo: $-0.55 Hi: $-0.40
11 analysts ▲3
+1q $-0.13
Lo: $-0.17 Hi: $-0.11
11 analysts ▲2
0q $-0.13
Lo: $-0.15 Hi: $-0.10
11 analysts ▲2
+1y $-0.54
Lo: $-0.66 Hi: $-0.38
10 analysts ▲2
Cross-Platform Signals
No cross-platform signals in the last 90 days